PSNL:NASDAQPersonalis, Inc. Analysis
Data as of 2026-05-19 - not real-time
$7.07
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Personalis trades around $7.07, just above its 20‑day simple moving average of 6.03 and near the 50‑day SMA of 6.50, but still below the 200‑day SMA of 7.51, indicating price pressure in a bearish technical environment.
The stock shows a bullish MACD histogram (+0.175) and a bullish signal line, yet RSI sits at 60.4 and the computed trend direction is flagged as bearish, combined with a beta of ~2.8 and a 30‑day volatility of 78 %, pointing to high market sensitivity and price‑swing potential.
Fundamentals are weak – revenue contracted 24.9 %, operating margin is –2.08 %, trailing EPS is –1.02 and the company recorded a max drawdown of –55 %, while the balance sheet shows a debt‑to‑equity ratio of 15.2 and negative ROE, underscoring earnings risk. Nonetheless, Q1 news highlights a 26 % jump to 7,800 MRD tests and new CMS coverage for immunotherapy monitoring, which could fuel short‑term upside if the pipeline scales.
The stock shows a bullish MACD histogram (+0.175) and a bullish signal line, yet RSI sits at 60.4 and the computed trend direction is flagged as bearish, combined with a beta of ~2.8 and a 30‑day volatility of 78 %, pointing to high market sensitivity and price‑swing potential.
Fundamentals are weak – revenue contracted 24.9 %, operating margin is –2.08 %, trailing EPS is –1.02 and the company recorded a max drawdown of –55 %, while the balance sheet shows a debt‑to‑equity ratio of 15.2 and negative ROE, underscoring earnings risk. Nonetheless, Q1 news highlights a 26 % jump to 7,800 MRD tests and new CMS coverage for immunotherapy monitoring, which could fuel short‑term upside if the pipeline scales.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- bearish trend direction
- high 30‑day volatility (78 %)
- negative earnings and cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- 26 % increase in quarterly MRD test volume
- CMS expanded coverage for immunotherapy monitoring
- potential upside if MRD pipeline scales
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- structural sector risk in biotech diagnostics
- ongoing cash burn and high debt‑to‑equity
- need for sustained payer contracts and regulatory approval
Key Metrics & Analysis
Financial Health
Revenue Growth-24.90%
Profit Margin-148.11%
P/E Ratio-7.9
ROE-41.35%
ROA-21.41%
Debt/Equity15.22
P/B Ratio2.9
Op. Cash Flow$-79463000
Free Cash Flow$-42353248
Industry P/E27.2
Technical Analysis
TrendBearish
RSI60.4
Support$4.95
Resistance$7.39
MA 20$6.03
MA 50$6.50
MA 200$7.51
MACDBullish
VolumeStable
Fear & Greed Index89.38
Valuation
Target Price$10.86
Upside/Downside53.57%
GradeOvervalued
TypeValue
Risk Assessment
Beta2.81
Volatility78.46%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.